A team led by David Kostin said: “A vaccine would likely catalyze another move higher in EPS estimates, particularly for cyclicals.”
Goldman Sachs is optimistic the US stock market sell-off is almost over and keeps its S&P 500 3,600 year-end target
More Stories
Record Korean Cases; Trader’s Guide to Rollout: Virus Update
California Hits Record; Trader’s Guide to Rollout: Virus Update
AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push